Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chronic Myeloid Leukemia
ChemGenex launches multinational phase 2/3 study for CML patients with T315I mutation
July 14th, 2006
ChemGenex Pharmaceuticals (CXS; CXSP) announced that it has launched a new multinational phase 2/3 study evaluating the use of Ceflatonin (homoharringtonine, HHT) in patients with chronic, accelerated and blast-phase chronic myeloid leukemia (CML) who have the T315I bcr-abl point mutation, which is associated with resistance to Gleevec and two known tyrosine kinase inhibitors (TKIs) currently under development. The study will be conducted in both the United States and Europe and is projected to enroll up to 81 patients within 12 months. The primary endpoint will be hematologic response rate, and the secondary endpoint will be cytogenetic response rate. ...
Source: Genomics & Genetics Weekly (2006-07-14)
|
